Publication | Closed Access

RGD peptide conjugation results in enhanced antitumor activity of PD0325901 against glioblastoma by both tumor-targeting delivery and combination therapy

Neuro-oncologyMedicineImmune Checkpoint InhibitorCombination TherapyTumor TargetingAnti-cancer AgentCancer TreatmentPharmacologyGliomaEnhanced Antitumor ActivityTumor-targeting DeliveryBiomolecular Engineering